Parkinsonian Rigidity Shows Variable Properties Depending on the Elbow Joint Angle

Table 1

Patients’ clinical details.

Patient	Age; (yrs)	Gender	Disease; duration (yrs)		UPDRS score		Medication*
				Part III	Rigidity (R)	Rigidity (L)
1	79	M	4.5	30	2	1	C 2 mg; C/L 25/250 mg
2	85	M	1	21	1	1	Pra 0.375 mg
3	64	M	3	19	1	1	Pra 1.5 mg; C/L 20/200 mg
4	50	F	5.5	15	1	1	Per 0.9 mg; B/L 62.5/250 mg; T 1 mg
5	58	F	20	26	1	1	B/L 50/200 mg; A 200 mg; T 4.5 mg
6	76	F	8	39	2	2	C/L 20/200 mg
7	60	M	3.5	24	1	1	Pra 1.375 mg
8	77	F	4	29	1	1	Pra 1.5 mg; Per 0.15 mg
9	67	M	8	26	1	1	Pra 3 mg; Per 0.9 mg; B/L 75/300 mg; S 2.5 mg
10	70	F	4.5	43	1	1	Per 0.75 mg; C/L 20/200 mg
11	66	M	15	45	3	3	Per 0.75 mg; B/L 100/400 mg; E 400 mg; S 5 mg; T 4 mg
12	73	F	12.5	32	1	1	Pra 1.5 mg; Per 1.05 mg; B/L 75/300 mg; S 5 mg
13	58	M	9	28	2	3	Pra 1.5 mg; Per 0.75 mg; C/L 15/150
14	67	M	8.5	39	2	1	Per 0.75 mg; B/L 150/600; S 2.5 mg; T 2 mg
15	67	M	5	53	2	2	C 3 mg; C/L 15/150 mg
16	78	M	5.5	35	2	2	Pra 3 mg; B/L 75/300
17	47	M	9	24	1	2	Pra 2 mg; C 2 mg; B/L 50/200; A 300 mg
18	67	M	5.5	39	1	2	Pra 1.5 mg; Per 0.6 mg; C/L 30/300
19	67	F	3	45	2	3	No medication
20	69	M	4	49	4	3	B/L 25/100
21	72	M	5	49	2	3	Pra 1.5 mg; B/L 125/500
22	60	F	8	18	2	3	Pra 2 mg; C 1 mg; C/L 15/150
23	73	M	6	51	4	3	Per 0.15 mg; B/L 62.5/250; A 125 mg; T 2 mg
24	65	F	2.5	29	3	2	Pra 0.75 mg; C/L 10/100; S 2.5 mg; D 200 mg

∗C: cabergoline; C/L: carbidopa/levodopa; Pra: pramipexole; Per: pergolide; B/L: benserazide/levodopa; T: trihexyphenidyl; A: amantadin; S: selegiline; E: entacapone; D: droxidopa.